Catalyst Pharmaceuticals (NASDAQ:CPRX) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) saw unusually-strong trading volume on Thursday . Approximately 5,312,735 shares changed hands during trading, an increase of 263% from the previous session’s volume of 1,464,761 shares.The stock last traded at $31.1250 and had previously closed at $30.52.

Catalyst Pharmaceuticals News Roundup

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst for about $4.1 billion (USD 31.50 per share), a ~28% premium to recent VWAP; transaction was unanimously approved by both boards and is expected to close in Q3, creating a near-term cash floor for the stock. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD
• Positive Sentiment: Catalyst announced a settlement with Hetero Labs that licenses a generic FIRDAPSE to launch no earlier than January 2035 (pending FDA approval), resolving active patent suits and preserving FIRDAPSE exclusivity for the near–to–medium term. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: Zacks published a preview of CPRX’s Q1 results highlighting key metrics beyond headline EPS/revenue — useful for gauging whether the company’s latest commercial performance supports the valuation implied by the deal. Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
• Neutral Sentiment: Stephens reaffirmed an “equal weight” rating on CPRX, a non?directional signal that suggests analysts view the acquisition price as reasonable relative to risk/reward but not a strong catalyst for a higher independent valuation. Benzinga
• Negative Sentiment: Two investor?rights firms (Ademi LLP and Halper Sadeh LLC) have launched investigations into whether the $31.50 per?share deal delivers a fair price to public shareholders — such actions can lead to litigation, delays, or demands for a higher bid. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
• Negative Sentiment: Halper Sadeh LLC separately announced an investigation into the sale to Angelini (same concern about deal fairness); this increases the chance of proxy litigation or settlement demands that could affect timing or economics of the close. CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
• Negative Sentiment: Recent insider sales reported in public filings (multiple officers sold shares in the past six months) may be viewed negatively by some investors, though sales can be routine and are occurring alongside a cash?offer announcement. Catalyst Pharmaceuticals and Hetero Labs Ltd. Settle FIRDAPSE Patent Litigation

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CPRX shares. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a research note on Thursday. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Three investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $33.33.

Catalyst Pharmaceuticals Trading Up 2.1%

The firm has a market cap of $3.81 billion, a PE ratio of 18.45, a price-to-earnings-growth ratio of 1.00 and a beta of 0.72. The stock has a fifty day simple moving average of $25.17 and a two-hundred day simple moving average of $23.85.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CPRX. Parkside Financial Bank & Trust grew its holdings in shares of Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 469 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Catalyst Pharmaceuticals by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 472 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Catalyst Pharmaceuticals by 14.0% during the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 498 shares in the last quarter. Lifestyle Asset Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 3.4% during the fourth quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock worth $393,000 after purchasing an additional 553 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).